An index to brand-name drugs, generic drugs and health issues discussed in Drug Safety Newsletter articles. A list of drug safety alerts and communications can be found on the Index to Drug-Specific Information.

Acute Pancreatitis
     Exenatide, 12-14

Adalimumab
     Serious Skin Reactions, 18-22

Aplastic Anemia
     Temozolomide, 7-8

Byetta, 12-14

Cialis, 15-17

Cymbalta, 22-24

Deferasirox, 8-9

Duloxetine, 22-24

Enbrel, 18-22

Etanercept
     Serious Skin Reactions, 18-22

Exenatide
     Acute Pancreatitis, 12-14

Exjade, 8-9

Hearing Loss
     PDE-5 Inhibitors, 15-17
     Sildenafil, 15-17
     Tadalafil, 15-17
     Vardenafil, 15-17

Humira, 18-22

Infliximab
     Serious Skin Reactions, 18-22

Levitra, 15-17

Modafinil
     Serious Skin Reactions, 5-7

PDE-5 Inhibitors
     Hearing Loss, 15-17

Pharmacogenomics, 24-26

PML (Progressive Multifocal Leukoencephalopathy), 3-5

Progressive Multifocal Leukoencephalopathy (PML), 3-5

Provigil, 5-7

Remicade, 18-22

Revatio, 15-17

Rituxan, 3-5

Rituximab
     Progressive Multifocal Leukoencephalopathy (PML), 3-5

Serious Skin Reactions
     Adalimumab, 18-22
     Etanercept, 18-22
     Infliximab, 18-22
     Modafinil, 5-7
     TNF-α Antagonists, 18-22

Sildenafil
     Hearing Loss, 15-17

Tadalafil
     Hearing Loss, 15-17

Temodar, 7-8

Temozolomide
     Aplastic Anemia, 7-8

TNF-α Antagonists
     Serious Skin Reactions, 18-22

Vardenafil
     Hearing Loss, 15-17

Viagra, 15-17